ES2863274T3 - Biomarcador de muerte celular - Google Patents
Biomarcador de muerte celular Download PDFInfo
- Publication number
- ES2863274T3 ES2863274T3 ES17771553T ES17771553T ES2863274T3 ES 2863274 T3 ES2863274 T3 ES 2863274T3 ES 17771553 T ES17771553 T ES 17771553T ES 17771553 T ES17771553 T ES 17771553T ES 2863274 T3 ES2863274 T3 ES 2863274T3
- Authority
- ES
- Spain
- Prior art keywords
- bap1
- protein
- wild
- type
- cell death
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
- G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un método para determinar si la célula cancerosa de un individuo es sensible a la muerte celular inducida por ligando del receptor de muerte (DRL), el método comprende detectar, en una muestra biológica tomada del individuo, para: (i) la presencia de un gen BAP1 mutante o proteína BAP1 mutante; (ii) un nivel reducido de expresión de un gen BAP1 de tipo salvaje o una concentración de proteína BAP1 de tipo salvaje más baja en comparación con el nivel de expresión o la concentración de proteína en una célula de referencia que es una célula con BAP1 de tipo salvaje, que es resistente a la muerte celular inducida por DRL; o (iii) la reducción o no unión de una proteína ASXL a una proteína BAP1 de tipo salvaje en comparación con el nivel de unión en una célula de referencia que es una célula con BAP1 de tipo salvaje, que es resistente a la muerte celular inducida por DRL; en donde la presencia, en la muestra, del mutante del gen BAP1 o la proteína BAP1 mutante, o de un nivel reducido de expresión del gen BAP1 de tipo salvaje o una concentración de proteína más baja, o la reducción o no unión de una proteína ASXL a una proteína BAP1 de tipo salvaje, es indicativo de que la célula cancerosa del individuo es sensible a la muerte celular inducida por DRL.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1615842.0A GB201615842D0 (en) | 2016-09-16 | 2016-09-16 | Cell death biomarker |
| PCT/GB2017/052733 WO2018051110A1 (en) | 2016-09-16 | 2017-09-15 | Cell death biomarker |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2863274T3 true ES2863274T3 (es) | 2021-10-11 |
Family
ID=57288813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17771553T Active ES2863274T3 (es) | 2016-09-16 | 2017-09-15 | Biomarcador de muerte celular |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11789012B2 (es) |
| EP (1) | EP3513192B1 (es) |
| JP (1) | JP7211936B2 (es) |
| AU (1) | AU2017327994B2 (es) |
| DK (1) | DK3513192T3 (es) |
| ES (1) | ES2863274T3 (es) |
| GB (1) | GB201615842D0 (es) |
| WO (1) | WO2018051110A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| CN112961864A (zh) * | 2021-02-26 | 2021-06-15 | 广州市妇女儿童医疗中心 | 突变的asxl3基因及应用 |
| CN114478797B (zh) * | 2021-11-24 | 2023-10-27 | 中山大学附属第五医院 | 一种靶向ddx24蛋白的水解靶向嵌合体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070037165A1 (en) | 2000-09-08 | 2007-02-15 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| US20020169123A1 (en) | 2001-02-27 | 2002-11-14 | The Trustees Of The University Of Pennsylvania | Regulating apoptosis in TRAIL-resistant cancer cells, while protecting normal, non-cancerous cells |
| RU2450273C2 (ru) | 2006-06-20 | 2012-05-10 | Дженентек, Инк. | Способы и материалы для обнаружения апоптоза |
| WO2012040614A1 (en) * | 2010-09-23 | 2012-03-29 | The Washington University | Compositions and methods for detecting cancer metastasis |
| EP2676134A4 (en) | 2011-02-16 | 2015-04-08 | Sloan Kettering Inst Cancer | BAP1 MUTATION ANALYSIS IN DETERMINING THE EVENT OF, PROGNOSIS AND TREATMENT OF MELANOCYTARY NEOPLASIA |
| JP6108571B2 (ja) | 2013-03-28 | 2017-04-05 | 国立大学法人東北大学 | 食道癌の発症リスクを判定する方法及びキット |
| AU2014331777A1 (en) | 2013-10-10 | 2016-05-05 | The Regents Of The University Of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| US20160101071A1 (en) * | 2014-04-28 | 2016-04-14 | Wisconsin Alumni Research Foundation | Combination cancer treatment |
| AU2015271099A1 (en) | 2014-06-02 | 2017-01-12 | Pharmakea, Inc. | Deubiquitinase inhibitors |
| JP6684230B2 (ja) | 2014-06-19 | 2020-04-22 | メモリアル スローン ケタリング キャンサー センター | Ｅｚｈ２阻害剤への応答についてのバイオマーカー |
-
2016
- 2016-09-16 GB GBGB1615842.0A patent/GB201615842D0/en not_active Ceased
-
2017
- 2017-09-15 AU AU2017327994A patent/AU2017327994B2/en active Active
- 2017-09-15 EP EP17771553.9A patent/EP3513192B1/en active Active
- 2017-09-15 US US16/333,590 patent/US11789012B2/en active Active
- 2017-09-15 WO PCT/GB2017/052733 patent/WO2018051110A1/en unknown
- 2017-09-15 JP JP2019514263A patent/JP7211936B2/ja active Active
- 2017-09-15 ES ES17771553T patent/ES2863274T3/es active Active
- 2017-09-15 DK DK17771553.9T patent/DK3513192T3/da active
-
2023
- 2023-04-12 US US18/299,415 patent/US20240118266A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017327994B2 (en) | 2023-09-14 |
| GB201615842D0 (en) | 2016-11-02 |
| JP2020500502A (ja) | 2020-01-16 |
| EP3513192A1 (en) | 2019-07-24 |
| US20240118266A1 (en) | 2024-04-11 |
| US11789012B2 (en) | 2023-10-17 |
| JP7211936B2 (ja) | 2023-01-24 |
| EP3513192B1 (en) | 2020-12-23 |
| WO2018051110A1 (en) | 2018-03-22 |
| US20190257818A1 (en) | 2019-08-22 |
| AU2017327994A1 (en) | 2019-04-04 |
| DK3513192T3 (da) | 2021-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022001463A (es) | Metodo y sistema para la determinacion no destructiva in ovo del genero aviar. | |
| EA201991105A1 (ru) | Методы оценки риска с использованием общей и специфической неклеточной днк | |
| MX2008009592A (es) | Metodos y composiciones para identificar pacientes con una probabilidad incrementada de tener cancer de ovario. | |
| TR201907389T4 (tr) | Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem. | |
| EP3839510A3 (en) | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists | |
| EP4180531A3 (en) | Nasal epithelium gene expression signature and classifier for the prediction of lung cancer | |
| AR095363A1 (es) | Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1 | |
| EA201070349A1 (ru) | Определение вариаций количества копий, способы и системы | |
| MX2015011362A (es) | Metodo para el pronostico y tratamiento de metastasis de cancer. | |
| ES2863274T3 (es) | Biomarcador de muerte celular | |
| MX343607B (es) | Receptor alfa de folato como marcador de diagnóstico y pronóstico para cánceres que expresan receptor alfa de folato. | |
| PH12015502849A1 (en) | Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers | |
| NZ629074A (en) | Biomarkers for gastric cancer and uses thereof | |
| WO2006055880A3 (en) | Diagnostic pkm2 methods and compositions | |
| AR099856A1 (es) | Métodos para diagnosticar y tratar la enfermedad de intestino inflamado | |
| HK1149956A1 (en) | Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex | |
| HK1115636A1 (en) | Use of cyfra 21-1 as a marker for colorectal cancer cyfra 21-1 | |
| EA201691505A1 (ru) | Детектирование экспрессии простатического специфического мембранного антигена (psma) на циркулирующих опухолевых клетках (ctc) | |
| Buser et al. | Quantitative proteomics reveals reduction of endocytic machinery components in gliomas | |
| ATE471512T1 (de) | Verwendung des proteins s100a 12 als marker für kolorektalkarzinom | |
| BR112017011545A2 (pt) | ensaio de desvio de mobilidade homogênea indireto para a detecção de produtos biológicos nas amostras do paciente | |
| MX2016009490A (es) | Ensayo novedoso para detectar periostina humana. | |
| ATE468535T1 (de) | Verwendung von nnmt als marker für lungenkrebs | |
| PE20120592A1 (es) | Metodo con biomarcadores para el seguimiento de un tratamiento | |
| EP2475789A4 (en) | METHODS FOR PREDICTING SENSITIVITY OF DISEASE OR DISORDER TO RECEPTOR TYROSINE KINASE INHIBITOR THROUGH MUTATION ANALYSIS IN PIK3CA GENE |